603387
vs
S
Shanghai Composite
603387
Over the past 12 months, Getein Biotech Inc has underperformed Shanghai Composite, delivering a return of +3% compared to the Shanghai Composite's +24% growth.
Stocks Performance
603387 vs Shanghai Composite
Performance Gap
603387 vs Shanghai Composite
Performance By Year
603387 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Getein Biotech Inc
Glance View
Getein Biotech, Inc. engages in the business of medical health industry chain. The company is headquartered in Nanjing, Jiangsu and currently employs 2,125 full-time employees. The company went IPO on 2017-07-17. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The firm also provides testing and agency services. The firm distributes its products within domestic market and to overseas markets.
